Skip to content
The Nexus
DossierENTITY

Human Longevity

Coverage of Human Longevity in the Nexus archive.

Earliest in view: May 27 · 00:30 UTCMost recent: Jul 2 · 23:14 UTC
Co-mentioned in this coverage
Insilico Medicineorganization2Hong Kongplace2AI foundation modelstopic2Iraperson1CA19-9topic1GRAIL Galleriorganization1BMItopic1pancreatic cancertopic1neurological conditionstopic1United Statesplace1Cancertopic1Global longevity markettopic1cancertopic1global longevity markettopic1USplace1
Recent coverage
  • HEALTHJul 2 · 23:14 UTCBUSINESS INSIDER
    My father died of cancer at 72. A $12,000 longevity exam at a Silicon Valley clinic found both good and bad news in my DNA.

    The author underwent a $12,000 longevity test at Human Longevity in Silicon Valley to assess cancer and other health risks after their father died of pancreatic cancer. The results showed a 99% chance of being cancer-free but revealed elevated risks for neurological conditions. The tests included genomic sequencing, blood work, and MRI scans.

  • HEALTHMay 27 · 00:30 UTCSCMP WORLD
    Insilico teams up with US firm to build AI models predicting disease decades ahead

    Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage advancements in AI and the growing $5.3 trillion global longevity market driven by aging populations.

  • HEALTHMay 27 · 00:30 UTCSCMP CHINA
    Insilico teams up with US firm to build AI models predicting disease decades ahead

    Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage the growing global longevity market, valued at $5.3 trillion.